Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
{{output}}
The phase 1-2 study CO-338-010 (Study 10; NCT01482715) is evaluating single-agent rucaparib, a poly(ADP-ribose) polymerase inhibitor, administered orally to patients with an advanced solid tumor. In the dose escalation phase (Part 1), we characterized the sing... ...
